Study of BMS-354825 in Subjects With CML Who Are Resistant to or Intolerant of Imatinib or Ph+All in Japan
Status:
Completed
Trial end date:
2007-03-01
Target enrollment:
Participant gender:
Summary
This study is composed of Phase I and Phase II part. Phase I part: The objective is to
evaluate the safety of BMS-354825 in subject with chronic phase Chronic Myelogenous Leukemia
(CML). Dosage of BMS-354825 will be 50 mg BID, 70 mg BID or 90 mg BID. Phase II part: The
objective is to evaluate the efficacy of BMS-354825. dosage will be decided according to the
results of Phase I part. Treatment period will be 6 months for subjects with chronic phase
CML, and 3 months for subjects with accelerated phase or blast phase CML and Philadelphia
Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ALL)